3.55 +0.04 (1.11%)
IPCI
| Trade IPCI now with |
|
Stock Details
Last Trade:3.55 Change:+0.04 (1.11%) Prev Close:3.51 Open: 3.59 Days Range:3.39 – 3.65 52 Week Range: 2.41 - 5.25 Volume:23074 P/E: N/AEPS:0.00
View AllRecent Alerts 02/08/12
Recent Alert on 11/28/11 at 6:36am
Intellipharmaceutics (IPCI) Files $30M Mixed Shelf
Intellipharmaceutics (IPCI) Files $30M Mixed Shelf
Intellipharmaceutics International, Inc. (Nasdaq: IPCI), filed a registration with the U.S. Securities and Exchange Commission to sell, from time to time, up to $30 million of Common Shares, Preference Shares, Warrants, Subscription Receipts, or any... Read More
Recent Alert on 11/15/11 at 7:09am
Intellipharmaceutics (IPCI) Toronto Facility Completes cGMP, Pre-Approval Inspection Process
Intellipharmaceutics (IPCI) Toronto Facility Completes cGMP, Pre-Approval Inspection Process
Recent Alert on 11/15/11 at 7:09am
Intellipharmaceutics (IPCI) Toronto Facility Completes cGMP, Pre-Approval Inspection Process
Intellipharmaceutics (IPCI) Toronto Facility Completes cGMP, Pre-Approval Inspection Process
View AllRecent Press Releases
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 11/18/11 at 8:01am
Intellipharmaceutics: A Deep Value Opportunity In Generics And Specialty Pharmaceuticals
Intellipharmaceutics: A Deep Value Opportunity In Generics And Specialty Pharmaceuticals
Blog Posts on 11/16/11 at 11:53am
Profitable Future Appears In Store For Intellipharmaceutics Shareholders
Profitable Future Appears In Store For Intellipharmaceutics Shareholders
Blog Posts on 11/01/11 at 10:42am
Intellipharmaceutics Reaches Key Milestone As Analysts Raise Price Targets Ahead Of Another One
Intellipharmaceutics Reaches Key Milestone As Analysts Raise Price Targets Ahead Of Another One
Blog Posts on 11/01/11 at 10:42am
Intellipharmaceutics Reaches Key Milestone As Analysts Raise Price Targets Ahead Of Another
Intellipharmaceutics Reaches Key Milestone As Analysts Raise Price Targets Ahead Of Another
Blog Posts on 06/24/11 at 8:26am
IntelliPharmaCeutics Investors Should Welcome Litigation Settlement
IntelliPharmaCeutics Investors Should Welcome Litigation Settlement